未找到相关数据
First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE
被引：4
作者：
Bachelot, Thomas Denis
Ciruelos, Eva
Peretz-Yablonski, Tamar
Puglisi, Fabio
Schneeweiss, Andreas
Campone, Mario
Coudert, Bruno P.
Kaufman, Bella
Wardley, Andrew M.
Bastiere-Truchot, Lydie
Freudensprung, Ulrich
Restuccia, Eleonora
Miles, David
机构：
[1] Ctr Leon Berard, Dept Oncol Med, F-69373 Lyon, France
[2] Univ Hosp 12 Octubre, Madrid, Spain
[3] Hadassah Hebrew Univ, Sharett Inst Oncol, Med Ctr, Jerusalem, Israel
[4] Univ Hosp Udine, Udine, Italy
[5] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
[6] Inst Cancerol Ouest, Nantes, France
[7] Ctr Georges Francois Leclerc, Dijon, France
[8] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[9] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[10] F Hoffmann La Roche, Basel, Switzerland
[11] Mt Vernon Canc Ctr, Northwood, Middx, England
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
548
引用
收藏
页数：2
相关论文